Delivery Order SPE2DR25D3021-SPE2DR26FS8GN
- Not listed
- The Defense Logistics Agency awarded a $16,998.05 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 14, 2025, with completion scheduled for July 15, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery is scheduled to occur at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $10,295.32 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Dupixent 300 mg/2 mL pen auto-injectors. The contract, which is classified as a child order under a larger vehicle, carries an ultimate completion date of September 17, 2025, and represents a competitive award with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $29,794.79 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on September 8, 2025, with completion targeted for September 9, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. AmerisourceBergen,...
- The Defense Logistics Agency awarded a $82,694.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on November 3, 2025, with an ultimate completion date of November 4, 2025. This is a non-set-aside competitively awarded contract for pharmaceutical supply to support federal medical procurement needs. The award was executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and serves as a child delivery order...
- The Defense Logistics Agency awarded a $39,157.60 delivery order to AmerisourceBergen Drug Corp for Dupixent 200 mg/1.14 mL pen injections on September 10, 2025, with completion scheduled for September 11, 2025. This firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The award was made on a non-set-aside, competitive basis and will be...
- The Defense Logistics Agency awarded a delivery order valued at $7,112.21 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors, with an ultimate completion date of September 9, 2025. This competitively awarded, firm fixed price order represents a single delivery transaction under AmerisourceBergen's larger contract vehicle with DLA. The contract was executed on September 8, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $12,257.90 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on November 4, 2025, with an ultimate completion date of November 5, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating it was awarded through open competition. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents...
- The Defense Logistics Agency awarded a $16,091.01 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on October 14, 2025, with completion scheduled for October 15, 2025. This is a firm fixed price, non-set-aside contract performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,674.11 to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Dupixent 300 mg/2 mL pen auto-injectors. This firm fixed-price delivery order, which is expected to be completed by November 7, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation and will be performed...
- The Defense Logistics Agency awarded a delivery order valued at $6,837.84 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 26, 2025, with completion scheduled for August 27, 2025. This competitively awarded, firm fixed-price delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply contract vehicle with DLA. The product will be delivered to the company's corporate headquarters in Conshohocken,...
- SPE2DR25D3021Indefinite Delivery Contract
- SPE2DR25D3021-SPE2DR26FS8GNDelivery Order
The Defense Logistics Agency awarded a $11,111.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent 200 mg/1.14 ml pen auto-injectors, with an ultimate completion date of November 18, 2025. This non-competitive, non-set-aside award was issued on November 17, 2025, with performance taking place at AmerisourceBergen's Corporate Office headquarters in Conshohocken, Pennsylvania. The delivery order represents a child contract action, likely executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. AmerisourceBergen serves as a critical pharmaceutical distributor for the Defense Logistics Agency's medical supply chain, supplying brand-name and generic medications, vaccines, and specialized medical devices to support military healthcare systems. Dupixent is a biologic immunosuppressant medication used to treat moderate-to-severe atopic dermatitis, eosinophilic asthma, and other inflammatory conditions, representing the type of specialty pharmaceutical product routinely procured through DLA's pharmaceutical prime vendor programs to support Defense Health Agency operations and broader federal healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.1k | 11/17/25 |